Partnering for Distribution Allows Greater Access
Irvine, CA – Red Chip Enterprises announces they have partnered with Emmaus Life Sciences, Inc. via a limited distribution network to allow Red Chip of Nevada Specialty Pharmacy to provide Emmaus’ Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. This agreement enables both companies to focus on their commitment to provide high quality care for patients with rare, chronic medical conditions.
“We are pleased to be able to offer this important medication to patients affected by sickle cell disease,” said Mary Ann Barth, co-founder of Red Chip Enterprises. “Our existing relationships with Hemophilia Treatment Centers will give us a unique opportunity to provide Endari to sickle cell patients, many of whom access the HTCs for treatment. In addition, our proven customer care model will offer patient education and promote compliance to the patient’s treatment plan.”
Mark Diamond, VP Commercialization at Emmaus Life Sciences commented: “We are happy to be working with Red Chip in our effort to provide Endari to a broader set of patients in the United States suffering from sickle cell disease.”
About Red Chip Enterprises
Red Chip Enterprises has been creating and revitalizing 340B Outpatient Factor Programs within Hemophilia Treatment Centers across the United States for the past 20 years. The natural progression into high touch pharmacy care for other bleeding disorders and their treatment allows us to continue our focus on achieving the best possible outcomes for patients with rare, chronic diseases. Red Chip Pharmacy is URAC accredited and can ship to all 50 states. For more information visit www.redchip.org.
About Endari® (L-glutamine oral powder)
Indication
Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Important Safety Information
The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain. Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash. The safety and efficacy of Endari in sickle cell disease patients younger than five years of age have not been established. For more information, please see full Prescribing Information of Endari at: www.ENDARIrx.com/PI.